Trending

GSK

Pharma companies clear the R&D decks in Q4

Pharma companies clear the R&D decks in Q4

The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as

X

Pharma companies clear the R&D decks in Q4

https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4/

GSK’s chairman Sir Philip Hampton steps down

GSK’s chairman Sir Philip Hampton steps down

GlaxoSmithKline is searching for a new chairman after Sir Philip Hampton announced he is to step down in

X

GSK’s chairman Sir Philip Hampton steps down

https://pharmaphorum.com/news/gsks-chairman-sir-philip-hampton-steps-down/

GSK enters PARP space with TESARO acquisition

GSK enters PARP space with TESARO acquisition

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its

X

GSK enters PARP space with TESARO acquisition

https://pharmaphorum.com/news/gsk-enters-parp-space-with-tesaro-acquisition/

GSK and Sanofi to Present the Opening Keynote Sessions

GSK and Sanofi to Present the Opening Keynote Sessions

Cold Chain Distribution Conference

X

GSK and Sanofi to Present the Opening Keynote Sessions

https://pharmaphorum.com/partner-content/gsk-and-sanofi-to-present-the-opening-keynote-sessions/

Tafenoquine – single shot malaria cure endorsed by the FDA advisers

Tafenoquine – single shot malaria cure endorsed by the FDA advisers

The US Food and Drugs Administration Advisory Committee has endorsed tafenoquine, a single-dose drug from the GSK pipeline

X

Tafenoquine – single shot malaria cure endorsed by the FDA advisers

https://pharmaphorum.com/news/tafenoquine-single-shot-malaria-cure-endorsed-by-the-fda/

GSK collaborates on AI-driven drug design with Cloud Pharmaceuticals

GSK collaborates on AI-driven drug design with Cloud Pharmaceuticals

GlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a

X

GSK collaborates on AI-driven drug design with Cloud Pharmaceuticals

https://pharmaphorum.com/news/gsk-ai-drug-design-cloud-pharmaceuticals/

GSK strengthens core prescription business with Sin hire

In a drive to boost its search for innovative products worldwide, GlaxoSmithKline (GSK) has hired Kevin Sin from

X

GSK strengthens core prescription business with Sin hire

https://pharmaphorum.com/news/gsk-strengthens-core-prescription-business-with-sin-hire/

GSK welcomes Brexit transition deal, but wants more ‘precision’ on final relationship

GSK welcomes Brexit transition deal, but wants more ‘precision’ on final relationship

The chief executive of GlaxoSmithKline has welcomed the breakthrough in talks between the UK and EU27 countries on a transition or ‘implementation’ period.

X

GSK welcomes Brexit transition deal, but wants more ‘precision’ on final relationship

https://pharmaphorum.com/news/gsk-welcomes-brexit-transition-deal-big-questions-medicines-remain/

GSK’s former chief Witty makes surprise move to ‘the dark side’

GSK’s former chief Witty makes surprise move to ‘the dark side’

GlaxoSmithKline’s former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.

X

GSK’s former chief Witty makes surprise move to ‘the dark side’

https://pharmaphorum.com/news/gsks-former-chief-witty-makes-surprise-move-dark-side/

1 2 3 4 5

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com